Health Monitor Liechtenstein: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Liechtenstein.

Press releases published on March 18, 2026

Mar. 18, 2026

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

Indeterminate GlobeNewswire

Mar. 18, 2026

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Indeterminate GlobeNewswire

Mar. 18, 2026

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire

Mar. 18, 2026

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Indeterminate GlobeNewswire

Mar. 18, 2026

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Indeterminate GlobeNewswire

Mar. 18, 2026

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

Indeterminate GlobeNewswire

Mar. 18, 2026

Verano Strengthens Retail Footprint in the Sunshine State with Opening of MÜV Lehigh Acres, the Company’s 84th Florida Dispensary and 161st Location Nationwide

Indeterminate GlobeNewswire

Mar. 18, 2026

Breckenridge Distillery Expands Its Colorado Presence with Cheba Hut Partnership

Indeterminate GlobeNewswire

Mar. 18, 2026

XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

Indeterminate GlobeNewswire

Mar. 18, 2026

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Indeterminate GlobeNewswire

Mar. 18, 2026

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Indeterminate GlobeNewswire

Mar. 18, 2026

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire

Mar. 18, 2026

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

Indeterminate GlobeNewswire

Mar. 18, 2026

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Indeterminate GlobeNewswire

Mar. 18, 2026

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Indeterminate GlobeNewswire

Mar. 18, 2026

Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice

Indeterminate GlobeNewswire

Mar. 18, 2026

Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR

Indeterminate GlobeNewswire

Mar. 18, 2026

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Indeterminate GlobeNewswire

Mar. 18, 2026

Valneva gibt die konsolidierten geprüften Finanzergebnisse für das Gesamtjahr 2025 bekannt

Indeterminate GlobeNewswire

Mar. 18, 2026

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Indeterminate GlobeNewswire